RHO and non-small cell lung carcinoma: The observation that down-regulation of DLC1 in NSCLC is associated with a poor clinical outcome [39] implies that targeting pro-oncogenic pathways activated by this down-regulation could be especially useful therapeutically, and inhibition of the RhoA pathway and Rho kinase, a downstream effector of Rho, are promising options for therapeutic interventions.